60例原发乳腺弥漫大B细胞淋巴瘤特征与生存分析
回顾性分析瑞金医院2013年11月至2022年9月收治的60例原发乳腺弥漫大B细胞淋巴瘤(PB-DLBCL)女性患者,44例行55个淋巴瘤相关基因靶向测序。5年PFS率66.5%、OS率90.6%,LDH升高和non-GCB型为不良预后因素,PIM1、MYD88、DTX1突变者预后差。
要点
- PB-DLBCL 5年OS率90.6%较高,但5年PFS率66.5%较低。
- LDH升高和non-GCB型是不良预后因素,多因素分析未发现独立因素。
- PIM1、MYD88、DTX1突变预后差,MPEG1突变预后良好。
核心结论
- PB-DLBCL患者5年OS率较高而PFS率较低。
- LDH升高、non-GCB型是影响患者生存的不良预后因素。
- PIM1、MYD88、DTX1突变的患者预后不佳,MPEG1突变的患者预后良好。
研究设计与样本
- 回顾性收集上海交通大学医学院附属瑞金医院2013年11月至2022年9月收治的60例PB-DLBCL患者临床资料。
- 其中44例患者进行靶向测序,覆盖55个淋巴瘤相关基因。
主要发现
- 60例均为女性,中位年龄56.5岁(49.0,61.0)。
- 总体5年PFS率66.5%(95% CI:51.0%~86.7%),5年OS率90.6%(95% CI:80.5%~100%)。
- 一线治疗后完全缓解率96.7%(58/60)。
- 单因素分析:LDH升高(HR=3.380,95% CI:1.160~9.791,P=0.025)和non-GCB型(HR=3.560,95% CI:1.000~12.700,P=0.049)是PFS不良预后因素;LDH升高(HR=6.212,95% CI:1.150~38.941,P=0.034)是OS不良预后因素。
- 多因素分析未发现PB-DLBCL患者PFS的独立不良预后因素。
关键数值与推荐
- PIM1、MYD88、KMT2D、CD79B、DTX1、MPEG1突变频率均高于20%。
- PIM1突变患者(27例)5年PFS率59.8%(95% CI:39.7%~90.0%)低于未突变患者(17例)80.7%(95% CI:58.3%~100%),P=0.019。
- MPEG1未突变患者(34例)5年PFS率59.4%(95% CI:41.0%~86.1%)低于突变患者(10例)100%,P=0.048。
- DTX1突变患者(10例)5年OS率48.0%(95% CI:18.8%~100%)低于未突变患者(34例)100%,P=0.004。
- MYD88突变患者(21例)5年OS率75.4%(95% CI:52.9%~100%)低于未突变患者(23例)100%,P=0.004。
临床怎么用
- 对PB-DLBCL患者应关注LDH水平和non-GCB分型以评估预后。
- 可考虑检测PIM1、MYD88、DTX1、MPEG1等基因突变辅助风险分层。
局限性
- 为单中心回顾性研究,样本量60例,靶向测序仅44例。
- 多因素分析未发现PFS独立不良预后因素,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the characteristics and prognostic factors of primary breast diffuse large B-cell lymphoma (PB-DLBCL) . Methods: Clinical data on 60 patients with PB-DLBCL admitted to Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, from November 2013 to September 2022, were respectively collected, and survival and prognostic analyses were conducted. Among them, 44 patients underwent targeted sequencing (of 55 lymphoma-related genes) to assess the gene mutation status and its impact on survival outcomes. Results: All 60 patients with PB-DLBCL were female. The median age was 56.5 years (49.0, 61.0). The overall 5-year progression-free survival (PFS) rate was 66.5% (95% CI: 51.0% -86.7% ), and the 5-year overall survival (OS) rate was 90.6% (95% CI: 80.5% -100.0% ). After one-line treatment, 96.7% (58 patients) achieved complete remission (CR). The results of univariate analysis showed that elevated LDH (HR=3.380, 95% CI: 1.160-9.791, P=0.025) and nongerminal center B-cell (non-GCB) type (HR=3.560, 95% CI: 1.000-12.700, P=0.049) were adverse prognostic factors for PFS in patients with PB-DLBCL, whereas elevated LDH (HR=6.212, 95% CI: 1.150-38.941, P=0.034) was an adverse prognostic factor for OS. Multivariate analysis did not identify independent adverse prognostic factors for PFS in patients with PB-DLBCL. Targeted sequencing results showed that the mutation frequencies of PIM1, MYD88, KMT2D, CD79B, DTX1, and MPEG1 were >20%. Log-rank test revealed that patients with PIM1 mutations (n=27) had a significantly lower 5-year PFS rate compared to those without mutations (n=17) [59.8% (95% CI: 39.7% -90.0% ) vs 80.7% (95% CI: 58.3% -100% ), P=0.019]. Regarding MPEG1, patients without mutations (n=34) exhibited a significantly lower 5-year PFS rate than those with mutations (n=10) [59.4% (95% CI: 41.0% -86.1% ) vs 100%, P=0.048]. For DTX1, patients with mutations (n=10) had a significantly lower 5-year OS rate than those without mutations (n=34) [48.0% (95% CI: 18.8% -100% ) vs 100%, P=0.004]. Similarly, patients with MYD88 mutations (n=21) showed a significantly lower 5-year OS rate than those without mutations (n=23) [75.4% (95% CI: 52.9% -100% ) vs 100%, P=0.004]. Conclusion: The 5-year OS rate of PB-DLBCL is relatively high, whereas the PFS rate is relatively low. Elevated LDH levels and having the non-GCB type are adverse prognostic factors affecting patient survival. The mutation frequencies of PIM1, MYD88, KMT2D, CD79B, DTX1, and MPEG1 are higher in PB-DLBCL. Patients with mutations in PIM1, MYD88, and DTX1 have a poor prognosis, whereas those with MPEG1 mutations have a favorable prognosis. 目的: 探究原发乳腺弥漫大B细胞淋巴瘤(PB-DLBCL)特征及预后相关因素。 方法: 回顾性收集上海交通大学医学院附属瑞金医院从2013年11月到2022年9月收治的60例PB-DLBCL患者的临床资料,并进行生存和预后因素分析。其中44例患者进行靶向测序(55个淋巴瘤相关基因)以评估基因突变情况及对生存结局的影响。 结果: 60例PB-DLBCL患者均为女性,中位年龄为56.5(49.0,61.0)岁,患者总体5年无进展生存(PFS)率和总生存(OS)率分别为66.5%(95% CI:51.0%~86.7%)和90.6%(95% CI:80.5%~100%)。一线治疗后完全缓解率为96.7%(58/60)。单因素分析结果显示LDH升高(HR=3.380,95% CI:1.160~9.791,P=0.025)、非生发中心来源(non-GCB)型(HR=3.560,95% CI:1.000~12.700,P=0.049)是PB-DLBCL患者PFS的不良预后因素,LDH升高是患者OS的不良预后因素(HR=6.212,95% CI:1.150~38.941,P=0.034)。多因素分析未发现PB-DLBCL患者PFS的独立不良预后因素。靶向测序结果显示,PIM1、MYD88、KMT2D、CD79B、DTX1、MPEG1突变频率均高于20%。Log-rank检验分析显示PIM1突变患者(27例)的5年PFS率低于未突变患者(17例)[59.8%(95% CI:39.7%~90.0%)对80.7%(95% CI:58.3%~100%),P=0.019];MPEG1未突变患者(34例)的5年PFS率低于突变患者(10例)[59.4%(95% CI:41.0%~86.1%)对100%,P=0.048];DTX1突变患者(10例)的5年OS率低于未突变患者(34例)[48.0%(95% CI:18.8%~100%)对100%,P=0.004];MYD88突变患者(21例)的5年OS率低于未突变患者(23例)[75.4%(95% CI:52.9%~100%)对100%,P=0.004]。 结论: PB-DLBCL患者5年OS率较高,PFS率较低。LDH升高、non-GCB型是影响患者生存的不良预后因素。PIM1、MYD88、KMT2D、CD79B、DTX1、MPEG1在PB-DLBCL中突变频率较高,PIM1、MYD88、DTX1突变的患者预后不佳,MPEG1突变的患者预后良好。.
引用
- Zhang HQ, He JY, Chen SY, et al. [Characteristics and survival analysis of 60 cases of primary diffuse large B-cell lymphoma of the breast]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42161661. doi:10.3760/cma.j.cn121090-20251110-00519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。